News

Disorders of consciousness after stroke

20% patients suffer from DoC after stroke
read more

CAPTAIN Trial - Positive Results in TBI

NEW study available - Efficacy and safety of Cerebrolysin® in neurorecovery after moderate-severe TBI: results from CAPTAIN
read more
1 … 47 48 49 50 51 … 67
1 … 34
Go to Archive

Congresses

11th European Stroke Organisation Conference

Helsinki, Finland
21 - 23 May 2025
GO TO EVENT

17th World Stroke Congress

Barcelona, Spain
22 - 25 October 2025
GO TO EVENT

Notice to U.S. Visitors

Please be advised that Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.

Cerebrolysin is a prescription medication for use under the supervision of an authorized health care professional. For any medical inquiries, please consult with a healthcare professional.